Glaukos Q2 Sales Surge 50% to $185.6M, Full-Year Guidance Raised to $680-$700M
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (3.0× avg).
Summary
Glaukos reported Q2 2026 net sales of $185.6 million, up 50% year-over-year, and raised full-year guidance to $680-$700 million. Gross margin improved to 82%, and the operating loss narrowed. The results highlight strong iDose TR adoption and the early commercial launch of Epioxa.
Key Events · Earnings and Guidance · GKOS
-
Q2 Sales Surge 50%
Net sales reached $185.6 million, up 50% from $124.1 million a year ago, driven by 64% growth in U.S. glaucoma sales from iDose TR and a 48% increase in corneal health sales from the Epioxa launch.
-
Full-Year Guidance Raised
Management raised 2026 revenue guidance to $680-$700 million, up from prior expectations, reflecting strong momentum in iDose TR and Epioxa.
-
Gross Margin Expands to 82%
Gross margin improved to 82% from 78% a year ago, benefiting from higher-margin iDose TR and Epioxa sales, despite increased amortization of intangible assets.
-
Operating Loss Narrows
Loss from operations narrowed to $17.3 million from $22.7 million, as revenue growth outpaced a 41% increase in operating expenses driven by higher stock-based compensation and commercial investments.
Analysis · GKOS · Industrial Applications And Services
A standout quarter for Glaukos saw net sales jump 50% year-over-year to $185.6 million, fueled by 64% growth in U.S. glaucoma sales from iDose TR adoption. Gross margin expanded to 82%, and the operating loss narrowed. Reflecting confidence in the commercial ramp of iDose TR and the controlled launch of Epioxa, management raised full-year 2026 guidance to $680-$700 million. The stock is trading near its 52-week high, underscoring market optimism, but the filing also flags risks: proposed LCDs from five MACs could restrict iDose TR coverage, and the transition from Photrexa to Epioxa may cause near-term disruption in corneal health. With $286 million in cash and investments, the company has ample runway to fund its growth initiatives.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GKOS was trading at $175.60 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $73.16 to $166.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.